Hiroaki Nagano

Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

Aim Microvascular invasion (MVI) affects the prognosis and treatment of hepatocellular carcinoma (HCC); however, its preoperative diagnosis is challenging. Analysis of computed tomography (CT) images using radiomics can detect MVI, but its effectiveness depends on the imaging conditions. We compared the efficacies of radiomics, clinical, and combined models for predicting MVI in HCC using nonstandardized scanning protocols. Methods This multicenter study included 533 patients who underwent hepatic resection for HCC. Patients were divided randomly into training ( n = 426) and test groups ( n = 107). We manually extracted 3D CT features in hepatic arterial, portal venous, and venous phases. The radiomics model was trained by machine learning. A logistic regression model was developed based on clinical information, and a fused model was created integrating clinical information and radiomics prediction score (Rad_Score). We calculated areas under the receiver operating characteristic curves (AUCs) for the radiomics, clinical, and mixed models in the test groups. Results The clinical model incorporated hepatitis B virus surface antigen, tumor diameter, and log‐transformed α ‐fetoprotein and des‐gamma‐carboxyprothrombin. The AUCs of the radiomics and clinical models were comparable ( p = 0.76). Rad_Score was not an independent significant factor in the fused model ( p = 0.40) and its addition did not improve the accuracy of the clinical model alone ( p = 0.51). Conclusions A clinical model is as effective as a CT radiomics model for predicting MVI status in patients with HCC based on real‐world scanning data, and integration of both models does not improve the predictive performance compared with a clinical model alone.

Year:

2024

Aim Neoadjuvant transcatheter arterial chemoembolization (TACE) for large tumors is controversial, especially in the minimally invasive surgery era. The aim of this study was to compare features between groups treated with neoadjuvant TACE followed by surgery (TACE + surgery) or upfront surgery for hepatocellular carcinoma >5 cm. Methods In this exploratory, multicenter, randomized phase I study, the primary measure was 2‐year disease‐free survival (DFS). Secondary measures were resection rate, necrosis rate by TACE, 2‐year overall survival, and site of recurrence. A total of 30 patients were randomly allocated to each arm. Results The two arms did not differ in patient characteristics. The median time to surgery from randomization was 48 days for TACE + surgery and 29 for surgery only ( p < 0.001). Postoperative morbidities did not differ between arms. The 2‐year DFS, overall survival, and resection rates were 56.7%, 80.0%, and 93.3%, respectively, in the TACE + surgery arm, and 56.1%, 89.9%, and 90.0% in the upfront surgery arm. Minimally invasive surgery was carried out in 35.7% in the TACE + surgery arm and in 29.6% in the upfront surgery arm. The median necrosis rate by TACE was 90.0%. In resected specimens, invasion to the hepatic vein was less with TACE + surgery (3.6% vs. 22.2%, p = 0.0380). In cases of 100% necrosis with TACE, 2‐year DFS was 100%. Site of recurrence did not differ between groups. Conclusion Neoadjuvant TACE did not improve 2‐year DFS, and neoadjuvant TACE allowed delay of surgical treatment without increased morbidity and cancer progress. Clinical trial registration UMIN: 000005241.

Year:

2024

Aim Developing effective adjuvant therapies is essential for improving the surgical outcomes in patients with hepatocellular carcinoma (HCC). Immunotherapy against HCC has become a promising strategy; however, only approximately 30% of all HCC patients respond to immunotherapy. Previously, we generated the novel therapeutic vaccine comprising multi‐human leukocyte antigen‐binding heat shock protein 70/glypican‐3 peptides with a novel adjuvant combination of hLAG‐3Ig and poly‐ICLC. We also confirmed the safety of this vaccination therapy, as well as its capacity for the effective induction of immune responses in a previous clinical trial. Methods In this phase I study, we administered this vaccine intradermally six times before surgery, and 10 times after surgery to patients with untreated, surgically resectable HCC (stage II to IVa). The primary end‐points of this study were the safety and feasibility of this treatment. We also analyzed the resected tumor specimens pathologically using hematoxylin–eosin staining and immunohistochemistry for heat shock protein 70, glypican 3, CD8 and programmed death‐1. Results A total of 20 human leukocyte antigen‐matched patients received this vaccination therapy with an acceptable side‐effect profile. All patients underwent planned surgery without vaccination‐related delay. Immunohistochemical analyses revealed that potent infiltration of CD8 + T cells into tumors with target antigen expression was observed in 12 of 20 (60%) patients. Conclusions This novel therapeutic vaccine was safe as perioperative immunotherapy for patients with HCC, and has the potential to strongly induce CD8 + T cells infiltration into tumors.

Year:

2023

Collaborators (4)

Susumu Eguchi

Professor

Nagasaki University

JAPAN
View details

Takehiro Noda

Associate Professor

Osaka University

JAPAN
View details

Atsushi Nanashima

-

JAPAN
View details

Toru Beppu

-

JAPAN
View details